About Event
What We Explored at the 2nd mRNA Analytical Development Summit Europe
At the 2nd mRNA Analytical Development, we addressed key challenges in purification, potency, manufacturing consistency, LNP payloads and heterogeneity. This summit was your opportunity to ask some of your burning questions, such as:
How can you maximise your mRNA characterisation to ensure safety, efficacy & quality of mRNA therapeutics and vaccines?
What are the different types of potency assays available to measure contaminants and bioreactivity to ensure safety for patients?
How can you complete high-quality LNP payload analysis to overcome stability hurdles and optimise mRNA delivery systems?
With world-class speakers from the likes of Moderna, AstraZeneca, GSK, Sanofi, Merck, and many more, 40+ global attendees united to remain at the forefront of advances in mRNA analytical development.
The Brand-New 2024 Agenda Snapshots
Discover what strategies are available to improve the specificity and reduce the potential for off-target effects of dsRNA. Discuss the regulatory hurdles within the detection of dsRNA to ensure the safety of these therapies with insights from Merck
Unveil the current stability studies aimed to modify the chemical structure of the mRNA cap to enhance specificity. Explore LNP payload analysis limitations and hurdles involved with delivering mRNA therapeutics to specific cells to maximise efficacy with insights from SanofiÂ
Delve into the latest innovations in the analytical toolbox and investigate the technologies specific to nucleic acid analysis. Focus on the toxicology aspects and enhancing manufacturing and analysis to elevate patient treatment outcomes and produce high quality and traceability mRNA medicines with insights from Ziphius Vaccines
This is your opportunity to remain up to date on the latest breakthroughs in analytical development from key stakeholders in the mRNA community!
Got Questions about event details? We are here to help!